Navigation Links
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Date:7/31/2013

HELSINKI, Finland, July 31, 2013 /PRNewswire/ --

Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus (Ad5/3-D24-GMCSF) for the treatment of soft tissue sarcoma.

     (Logo: http://photos.prnewswire.com/prnh/20130731/630919)

"We are pleased to receive orphan drug designations for CGTG-102 from the two leading regulatory agencies in the world. These designations confirm the need for developing novel therapies for rare cancers and are an important step in the development of CGTG-102" ,said Frans Wuite, M.D., President and Chief Executive Officer of Oncos.

Orphan Drug Designation applies to drugs that seek to treat rare diseases or conditions for which there may be few adequate therapies. In USA, the designation will provide Oncos with the opportunity of seven years of marketing exclusivity, grant funding to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA's application user fee. Similarly, incentives are provided for Europe by EMA, which include fee reductions on future activities and the potential for 10 years market exclusivity.

About Soft Tissue Sarcoma

Soft tissue sarcoma is estimated to affect 3-4 in 10,000 people in the EU and US. About 50% of soft tissue sarcomas are found in the early stage and advanced stage patients have an average overall survival of 13 months with today's standard of care. Several efforts to develop additional chemotherapeutics for STS have failed, including two products in Phase III development this year. Novel therapies with a different mechanism of action are therefore needed.

About CGTG-102

Oncos' lead product candidate, CGTG-102, is an oncolytic immunotherapy based on a purposefully modified, GM-CSF encoding adenovirus that selectively replicates in tumor cells and eventually kills them. Upon tumor cell death, newly synthesized viruses are released and infect neighboring tumor cells. Simultaneously, tumor antigens are exposed activating a tumor specific, systemic response by the patient's immune system. This response is further enhanced by the CGTG-102 induced production of GM-CSF in tumor cells.
A Phase I study with CGTG-102, will be completed this year and Phase II studies are scheduled to start in 2014. Prior to the Phase I study, 115 patients with chemotherapy refractory solid tumors had been treated with CGTG-102 in an individualized treatment program regulated by the Finnish Medicines Agency as determined by the EU Regulation on Advanced Therapy Medicinal Products, EC/1394/2007.

About Oncos Therapeutics

Oncos Therapeutics Ltd is a privately owned, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapy products for solid tumors. The company's lead investor is HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe. Oncos is headquartered in Helsinki, Finland and has an office in Switzerland. For more information about Oncos, please visit http://www.oncos.com.

 


'/>"/>
SOURCE Oncos Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
2. OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
3. OncoSec Medical to Present at the 25th Annual Roth Conference
4. OncoSec Medical Promotes Veronica Vallejo to Chief Financial Officer
5. OncoSec Medical to Present at the 15th Annual BIO CEO & Investor Conference
6. OncoSec Medical to Present at Noble Financial Capital Markets Ninth Annual Equity Conference on January 22
7. OncoSec Medical Announces $7.2 Million Public Offering
8. OncoSec Medical to Present Data at DNA Vaccines 2012 Conference
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec to Present at Upcoming Healthcare and Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
(Date:5/3/2017)...  Kalorama Information notes that transplant diagnostics is ... and this is projected to continue to 2021. ... or bone marrow transplants require histocompatibility between the ... this task. This according to a new report ... various PCR-based methodologies, Sanger sequencing and NGS used ...
Breaking Medicine Technology:
(Date:5/28/2017)... ... May 28, 2017 , ... Starting in May, patients at The Bay ... Variability (HRV) diagnostic test. , Nerve-Express, originally designed for the Navy in the 1980s, ... of a patient’s autonomic nervous system (ANS). The ANS controls all the critical ...
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... Mediaplanet ... & Wound Care" campaign in USA Today, which will educate readers on how to ... of the campaign, a large focus is placed on melanoma. Dancing with the Stars ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider ... monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep ... With this platform, initializing devices and importing studies are just one-click operations. This ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
Breaking Medicine News(10 mins):